Evidence map›Paper›PMID 36145042›Full record

ArticleNanomaterials (Basel, Switzerland)2022

Highly Luminescent and Photostable Core/Shell/Shell ZnSeS/Cu:ZnS/ZnS Quantum Dots Prepared via a Mild Aqueous Route.

Salima Mabrouk, Hervé Rinnert, Lavinia Balan, Jordane Jasniewski, Sébastien Blanchard, Ghouti Medjahdi, Rafik Ben Chaabane, Raphaël Schneider

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Synergistic AlNanomaterials (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Salima MabroukUniversité de Lorraine, CNRS, LRGP, F-54000 Nancy, France.
Hervé RinnertUniversité de Lorraine, CNRS, IJL, F-54000 Nancy, France.
Lavinia BalanCEMHTI-UPR 3079 CNRS, Site Haute Température, 1D Avenue de la Recherche Scientifique, 45071 Orléans, France.ORCID 0000-0003-0144-401X
Jordane JasniewskiUniversité de Lorraine, LIBio, F-54000 Nancy, France.
Sébastien BlanchardSorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire, IPCM, F-75005 Paris, France.ORCID 0000-0002-5072-5160
Ghouti MedjahdiUniversité de Lorraine, CNRS, IJL, F-54000 Nancy, France.
Rafik Ben ChaabaneLaboratoire Interfaces et Matériaux Avancés, LIMA, LR011ES55, Faculté des Sciences de Monastir, Avenue de l'Environnement, Monastir 5019, Tunisia.
Raphaël SchneiderUniversité de Lorraine, CNRS, LRGP, F-54000 Nancy, France.ORCID 0000-0002-6870-6902

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An aqueous-phase synthesis of 3-mercaptopropionic acid (3-MPA)-capped core/shell/shell ZnSeS/Cu:ZnS/ZnS QDs was developed. The influence of the Cu-dopant location on the photoluminescence (PL) emission intensity was investigated, and the results show that the introduction of the Cu dopant in the first ZnS shell leads to QDs exhibiting the highest PL quantum yield (25%). The influence of the Cu-loading in the dots on the PL emission was also studied, and a shift from blue-green to green was observed with the increase of the Cu doping from 1.25 to 7.5%. ZnSeS/Cu:ZnS/ZnS QDs exhibit an average diameter of 2.1 ± 0.3 nm and are stable for weeks in aqueous solution. Moreover, the dots were found to be photostable under the continuous illumination of an Hg-Xe lamp and in the presence of oxygen, indicating their high potential for applications such as sensing or bio-imaging.

Indexed as

core/shell/shell ZnSeS/Cu:ZnS/ZnS quantum dotsdopant locationoptoelectronic properties(photo)stability

Identifiers

PMID36145042
PMCPMC9504198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.